Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

November 17-18, 2017

New York, New York

Scientific Agenda

Friday, November 17, 2017

8:00 am

Welcome and introduction

Session I: Introductory lectures for the new millennium

8:10 am

Emerging role of liquid biopsy

8:30 am

Lung cancer screening and smoking cessation

8:55 am

Late-breaking topic to be announced

Session II: Early stage NSCLC

9:20 am

Pre-session ARS survey

9:25 am

Going beyond positron emission tomography (PET): New imaging approaches

9:50 am

Current best practices for adjuvant therapy

10:15 am

Panel Q & A

10:30 am

Post-session ARS survey

10:35 am

Break

Session III: Locally advanced NSCLC: The marriage of medical, radiation, and surgical oncology

10:55 am

Pre-session ARS survey

11:00 am

Combination therapy with targeted and immunotherapy agents

11:25 am

Radiation for locally advanced non-small cell lung cancer (NSCLC)

11:45 am

Advances in surgical management

12:05 pm

Panel Q & A

12:25 pm

Post-activity learner survey via ARS

12:30 pm

Lunch

Session IV: Special topics in lung cancer

2:00 pm

Pre-session ARS survey

2:20 pm

Mesothelioma

2:40 pm

Squamous cell carcinoma

3:00 pm

Thymic tumors and other thoracic zebras

3:20 pm

Late-breaking topic to be announced

3:40 pm

Panel Q & A

3:50 pm

Post-session ARS survey

4:00 pm

Adjourn

Saturday, November 18, 2017

8:00 am

Welcome and introduction

Session V: Advanced NSCLC

8:10 am

Pre-session ARS survey

8:15 am

Targeted therapy for advanced EGFR- positive disease

8:40 am

Managing EGFR-resistant disease

9:05 am

Role of monoclonal antibodies

9:30 am

Panel Q & A

9:45 am

Post-session ARS survey

10:00 am

Break

Session VI: Supportive therapy

10:20 am

Pre-session ARS survey

10:25 am

Patient education and treatment expectation management

11:50 am

Complementary and alternative therapy

12:15 pm

Shared decision making at the end of life

12:40 pm

Panel Q & A

12:55 pm

Post-session ARS survey

1:00 pm

Lunch

Session VII: Biomarkers and targeted therapy

2:30 pm

Pre-session ARS survey

2:35 pm

EML4/ALK, ROS-1, and other biomarkers: Therapeutic implications and the path forward

2:55 pm

Potential and progress in targeting HER2, BRAF, KRAS, MET, TRK, and RET

3:05 pm

Panel Q & A

3:20 pm

Post-session ARS survey

Session VIII: Immunotherapy and lung cancer

3:25 pm

Pre-session ARS survey

3:30 pm

Immunotherapy in lung cancer: Panacea vs reality?

3:50 pm

Immune checkpoint inhibitors

4:10 pm

Monitoring, mitigating, and managing immune-related adverse events

4:30 pm

Immunotherapy beyond immune checkpoint inhibitors

4:50 pm

Panel Q & A

5:05 pm

Post-session ARS survey

5:10 pm

Adjourn